SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-23-023426
Filing Date
2023-08-14
Accepted
2023-08-14 08:35:32
Documents
72
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q atos20230630_10q.htm   iXBRL 10-Q 1072967
2 EXHIBIT 31.1 ex_524818.htm EX-31.1 11192
3 EXHIBIT 31.2 ex_524819.htm EX-31.2 11100
4 EXHIBIT 32.1 ex_524820.htm EX-32.1 5991
5 EXHIBIT 32.2 ex_524821.htm EX-32.2 6122
11 g01.jpg GRAPHIC 149860
  Complete submission text file 0001437749-23-023426.txt   5226333

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA atos-20230630.xsd EX-101.SCH 52841
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE atos-20230630_cal.xml EX-101.CAL 30772
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE atos-20230630_def.xml EX-101.DEF 332090
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE atos-20230630_lab.xml EX-101.LAB 277460
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atos-20230630_pre.xml EX-101.PRE 359270
66 EXTRACTED XBRL INSTANCE DOCUMENT atos20230630_10q_htm.xml XML 589369
Mailing Address 107 SPRING STREET SEATTLE WA 98104
Business Address 107 SPRING STREET SEATTLE WA 98104 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

IRS No.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35610 | Film No.: 231166529
SIC: 2834 Pharmaceutical Preparations